Oral low-dose methotrexate improves infliximab pharmacokinetics, immunogenicity, and endoscopic outcomes in Crohn’s disease: a propensity score-adjusted real-world study
In patients with Crohn's disease, oral low-dose methotrexate combined with infliximab was associated with significantly improved endoscopic remission at week 26 compared to infliximab monotherapy, without a statistically significant increase in adverse events.
Authors
- Tingting Qin (ORCID: https://orcid.org/0000-0002-1975-9696)
- Shaoxin Huang (ORCID: https://orcid.org/0000-0001-9801-4133)
- Meng Ke
- Feng Tang (ORCID: https://orcid.org/0000-0001-9522-9649)
- Jiazhi Liao
- D. Li
- Juan Li (ORCID: https://orcid.org/0000-0002-1979-9049)
- Gong Jin
- Haoying Liu
- F Xiao
- Anqi Dai
- Li Wang
- Yinxian Shen
- Qionghui Huang
- Runzhao Ma
Institutions
- Wuhan University of Technology (CN)
- Hubei University of Science and Technology (CN)
- Wuhan No.1 Hospital (CN)
- Tongji Hospital (CN)
- Wuhan University of Science and Technology (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1007/s11096-026-02098-z
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Wu Jieping Medical Foundation
- National Key Research and Development Program of China